tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Leukoplakia D007971 1 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Lymphocele D008210 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Myelitis D009187 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Herpes Labialis D006560 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Vestibular Diseases D015837 2 associated lipids
Myxedema D009230 2 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Lymphomatoid Granulomatosis D008230 2 associated lipids
Paresis D010291 2 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Angiofibroma D018322 2 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Mediastinitis D008480 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Oliguria D009846 2 associated lipids
Hutchinson's Melanotic Freckle D018327 2 associated lipids
Fibroadenoma D018226 2 associated lipids
Mucinoses D017520 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Carobbi A et al. Effect of splenectomy in combination with FK 506 and 15-deoxyspergualin on cardiac xenograft survival. 1991 Transplant. Proc. pmid:1703704
Morris RE et al. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. 1990 Transplant. Proc. pmid:1689885
Todo S et al. Early trials with FK 506 as primary treatment in liver transplantation. 1990 Transplant. Proc. pmid:1689886
Scheel AK et al. Severe neurotoxicity of tacrolimus (FK506) after renal transplantation: two case reports. 2001 Nov-Dec Transplant. Proc. pmid:11750573
Morris-Stiff G et al. Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. 1998 Transplant. Proc. pmid:9636525
Wang XH et al. Tacrolimus vs CyA Neoral in combination with MMF and steroids after cadaveric renal transplantation. 2000 Transplant. Proc. pmid:11119899
Burke GW et al. Cholesterol control: long-term benefit of pancreas-kidney transplantation with FK 506 immunosuppression. 1998 Transplant. Proc. pmid:9532153
Aravot D et al. A new immunosuppressive protocol for lung transplantation: early promising results. 2003 Transplant. Proc. pmid:12644072
Gallego-Valcarce E et al. Conversion to tacrolimus extended-release formulation: short-term clinical results. 2009 Jul-Aug Transplant. Proc. pmid:19715909
Molleví DG et al. Late xenograft rejection: comparison between liver and heart xenografts under low-dose tacrolimus. 2002 Transplant. Proc. pmid:11959212
Cimsit B et al. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. 2011 Transplant. Proc. pmid:21486625
Zhao Y et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. 2005 Jan-Feb Transplant. Proc. pmid:15808586
Rajnoch J et al. Regulators of angiogenesis in renal ischemia/reperfusion injury in normotensive and hypertensive rats: effect of tacrolimus. 2005 Jan-Feb Transplant. Proc. pmid:15808641
Gunji Y et al. Pathologic characteristics of vasculitis in renal transplant recipient dogs receiving immunosuppressive agents, FK 506, rapamycin, or RS-61443. 1993 Transplant. Proc. pmid:7679841
Jain AB et al. Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. 1991 Transplant. Proc. pmid:1721274
McMichael J et al. Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. 1991 Transplant. Proc. pmid:1721275
Namii Y et al. Tetrahydropyranyladriamycin with FK 506 combination therapy for hamster-to-rat-concordant xenotransplantation. 1996 Transplant. Proc. pmid:8623358
Charpentier B An induction versus no-induction protocol in anticalcineurin-based immunosuppression using very low-dose steroids. 2001 Transplant. Proc. pmid:11406262
Ghobrial RM et al. Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. 1998 Transplant. Proc. pmid:9636597
Tashiro H et al. Donor bone marrow perioperatively administered via portal vein induced prolongation of skin allograft survival and microchimerism in liver-transplanted rats. 2000 Transplant. Proc. pmid:11120201
Jurewicz WA Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report. 1999 Transplant. Proc. pmid:10576048
Tarasewicz A et al. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. 2009 Transplant. Proc. pmid:19917366
San Segundo D et al. Study of B-cell subpopulations in lung transplant recipients with posttransplant infection. 2012 Transplant. Proc. pmid:23146491
Murata M et al. Unrelated donor bone marrow transplantation in Japanese patients is facilitated by the National Marrow Donor Program of the United States. 1998 Transplant. Proc. pmid:9474987
Tanabe K et al. Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid. 2004 Transplant. Proc. pmid:15518791
Jain AB et al. One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. 1995 Transplant. Proc. pmid:7533353
Zeevi A et al. In vitro assessment of FK 506 immunosuppressive activity in transplant patients. 1991 Transplant. Proc. pmid:1721307
Ziolkowski J et al. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. 2003 Transplant. Proc. pmid:14529923
Foroncewicz B et al. Anti-CD25 and tacrolimus therapy may not prevent early primary biliary cirrhosis recurrence after liver transplantation: two case reports. 2003 Transplant. Proc. pmid:14529924
Ushigome H et al. Pediatric living-related renal transplantation under tacrolimus as the primary immunosuppressive agent. 2003 Transplant. Proc. pmid:12591350
Kim SW et al. Decreased formation of nitric oxide in rats treated with FK506. 2003 Transplant. Proc. pmid:12591357
Nakamura Y et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. 2005 Transplant. Proc. pmid:15919445
Masuda S et al. Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients. 2005 Transplant. Proc. pmid:15919446
Ogino S et al. Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients. 2004 Transplant. Proc. pmid:15041357
Takaori K et al. Basic study on immunologic effects of cyclosporine and FK 506 for application to pancreatic transplantation. 1992 Transplant. Proc. pmid:1376531
Kuroki H and Ikuta Y Nerve regeneration of vascularized rat limb allograft and functional recovery of long-term graft survivals treated by short course of FK 506 or cyclosporine. 1995 Transplant. Proc. pmid:7533405
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation using the cuff technique in rats. 1992 Transplant. Proc. pmid:1376532
Ko S et al. Significance of newly developed liposomal FK 506 in canine liver transplantation. 1995 Transplant. Proc. pmid:7533406
Shaw BW et al. FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. 1991 Transplant. Proc. pmid:1721338
McDiarmid SV et al. FK 506 rescue therapy in liver transplantation: outcome and complications. 1991 Transplant. Proc. pmid:1721339
Böttiger Y et al. Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. 2002 Transplant. Proc. pmid:12176476
Orlandi V et al. Tacrolimus-associated myositis: a case report in a renal transplant patient. 2004 Transplant. Proc. pmid:15110639
Schorlemmer HU and Kurrle R Combination therapy of malononitrilamides and tacrolimus (FK 506) induced long-term xenograft survival. 1998 Transplant. Proc. pmid:9865337
de Oliveira Clark RM et al. Evaluation of hemodynamic, metabolic, and electrolytic changes after graft reperfusion in a porcine model of intestinal transplantation. 2010 Jan-Feb Transplant. Proc. pmid:20172287
Fischereder M et al. Gynaecomastia following solid organ transplantation. 2002 Transplant. Proc. pmid:12270376
Hohage H et al. Switching immunosuppression from cyclosporine to tacrolimus improves long-term kidney function: a 6-year study. 2005 Transplant. Proc. pmid:15919497
Perego C et al. Orthotopic liver-small bowel transplantation in pigs: study of immunologic parameters during therapy with FK 506-based immunosuppressive regimens. 1996 Transplant. Proc. pmid:8907908
Budde K et al. Five year outcome of tacrolimus rescue therapy in late rejection after renal transplantation. 2002 Transplant. Proc. pmid:12176499
Hayakawa K et al. Involvement of clonal deletion in immunotolerance induction: tests of Tacrolimus administration in rat renal transplantation. 1994 Transplant. Proc. pmid:7520608
Malaise J et al. Corticosteroid withdrawal in simultaneous pancreas-kidney transplantation: a 3-year report. 2005 Jul-Aug Transplant. Proc. pmid:16182832
Lorho R et al. Improved liver function and decreased hepatitis C viral load after tacrolimus was replaced by cyclosporine. 2005 Jul-Aug Transplant. Proc. pmid:16182838
Feitoza CQ et al. A role for HO-1 in renal function impairment in animals subjected to ischemic and reperfusion injury and treated with immunosuppressive drugs. 2007 Transplant. Proc. pmid:17362747
Fries D et al. Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. 1991 Transplant. Proc. pmid:1721370
Jain AB et al. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1703354
Soylu H et al. Survival of renal transplant patients: data from a tertiary care center in Turkey. 2015 Transplant. Proc. pmid:25769571
Nishimura Y et al. A trial to obtain donor-specific immunotolerance using a vascularized thymus allograft. 1998 Transplant. Proc. pmid:9838684
Damotte D et al. Morphologic features of large bowel biopsies in combined small and large bowel transplantations could predict clinical rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083252
Sanada O et al. Establishment of chimerism in donors by intraportal injection of recipient-type bone marrow cells with concomitant administration of FK 506 before liver transplantation prolongs liver allograft survival in rats. 1998 Transplant. Proc. pmid:9838689
Kandaswamy R et al. Vascular graft thrombosis after pancreas transplantation: comparison of the FK 506 and cyclosporine eras. 1999 Feb-Mar Transplant. Proc. pmid:10083254
Tashiro H et al. Correlation of high-level microchimerism with graft acceptance in rat liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123287
Ierardi E et al. Long-term tacrolimus: a promising therapeutic approach for Crohn's disease. 2001 Transplant. Proc. pmid:11377467
Guckelberger O et al. Does the choice of primary immunosuppression influence the prevalence of cardiovascular risk factors after liver transplantation? 1996 Transplant. Proc. pmid:8962230
Jørgensen KA et al. Two-hour blood tacrolimus levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal transplant patients. 2002 Transplant. Proc. pmid:12176551
Hatakeyama S et al. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients. 2012 Transplant. Proc. pmid:22310594
Jiang Y et al. Dyslipidemia in human kidney transplant recipients receiving cyclosporine and tacrolimus is associated with different expression of CD36 on peripheral blood monocytes. 2011 Transplant. Proc. pmid:21693242
Aono T et al. Minimal threshold of FK 506 for enhancing liver regeneration in thymectomized rats. 1995 Transplant. Proc. pmid:7536981
Lauro A et al. Rejection episodes and 3-year graft survival under sirolimus and tacrolimus treatment after adult intestinal transplantation. 2007 Transplant. Proc. pmid:17580204
Morrisett JD et al. Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. 1991 Transplant. Proc. pmid:1721402
Kobayashi N et al. Abdominal organ cluster transplantation in pigs receiving FK 506. 1992 Transplant. Proc. pmid:1379754
Jordan ML et al. Tacrolimus rescue therapy for renal transplant rejection. 1996 Transplant. Proc. pmid:8769174
Kuroki H et al. Experimental studies of vascularized allogeneic limb transplantation in the rat using a new immunosuppressive agent, FK-506: morphological and immunological analysis. 1989 Transplant. Proc. pmid:2468255
Ishibashi M et al. Experimental study of tacrolimus immunosuppression on the mode of administration: efficacy of constant intravenous infusion avoiding C(max). 2001 Feb-Mar Transplant. Proc. pmid:11266958
Braun N et al. Impairment of renal function following liver transplantation. 2003 Transplant. Proc. pmid:12826191
Van Buren D et al. Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients. 1998 Transplant. Proc. pmid:9723299
Taber DJ et al. Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient. 2000 Transplant. Proc. pmid:10812156
Morrissey PE et al. Factors contributing to acute rejection in renal transplantation: the role of noncompliance. 2005 Transplant. Proc. pmid:15964334
El-Sabrout R et al. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients--a single center experience. 2003 Transplant. Proc. pmid:12742474
Formica RN et al. Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation. 2003 Transplant. Proc. pmid:12742475
Testillano M et al. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center. 2009 Transplant. Proc. pmid:19376421
Polanco N et al. Everolimus-based immunosuppression therapy for BK virus nephropathy. Transplant. Proc. pmid:25645770
Filler G et al. One-year glomerular filtration rate predicts graft survival in pediatric renal recipients: a randomized trial of tacrolimus vs cyclosporine microemulsion. 2002 Transplant. Proc. pmid:12176634
Hasegawa A et al. Optimal use of tacrolimus in living donor renal transplantation in children. 2002 Transplant. Proc. pmid:12176635
Tinti F et al. Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients. 2010 Transplant. Proc. pmid:21168623
Joo DJ et al. Comparison of the affinity column-mediated immunoassay and microparticle enzyme immunoassay methods as a tacrolimus concentration assay in the early period after liver transplantation. 2010 Transplant. Proc. pmid:21168645
Staak A et al. Immunoglobulin induction therapy in renal transplant recipients: Effects on immunoglobulin and regulatory antibody levels. 2006 Transplant. Proc. pmid:17175311
Wu GD et al. FK 506 inhibits the development of transplant arteriosclerosis. 1991 Transplant. Proc. pmid:1721433
Kobayashi N et al. Effect of FK 506 on abdominal organ cluster transplantation in pigs. 1991 Transplant. Proc. pmid:1721434
Todo S et al. Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. 1987 Transplant. Proc. pmid:2445076
Collier DS et al. Kidney transplantation in the dog receiving FK-506. 1987 Transplant. Proc. pmid:2445077
Martín-Fernández M et al. Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts. 2017 Transplant. Proc. pmid:29149986
Ott R et al. Does conversion of immunosuppressive monotherapy from cyclosporine A to tacrolimus improve bone mineral density in long-term stable liver transplant recipients? 2003 Transplant. Proc. pmid:14697971
García Meseguer C et al. The effect of different immunosuppression on the outcome of pediatric renal transplants. 1999 Transplant. Proc. pmid:10500577
Morena M et al. Low-density lipoprotein composition and oxidation are not influenced by calcineurin inhibitors in renal transplant patients. 2000 Transplant. Proc. pmid:11134805
Kanbay M et al. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. 2005 Transplant. Proc. pmid:16213325
Wojarski J et al. Immunosuppressive Treatment and Its Effect on the Occurrence of Pneumocystis jiroveci, Mycoplasma pneumoniae, Chlamydophila pnemoniae, and Legionella pneumophila Infections/Colonizations Among Lung Transplant Recipients. 2018 Transplant. Proc. pmid:30177108
Preston R et al. FK 506 as primary immunosuppressive therapy in renal transplantation. 1998 Transplant. Proc. pmid:9636493
Jensik SC Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. 1998 Transplant. Proc. pmid:9636494
Kanatani T et al. Experimental limb transplantation, part III: induction of tolerance in the rigorous strain combination of Brown Norway donor to Lewis recipient. 2004 Transplant. Proc. pmid:15686745
Groth CG Immunosuppressive regimens of tomorrow. 1995 Transplant. Proc. pmid:8539797
Hariharan S et al. Conversion from cyclosporine to tacrolimus after pancreas transplantation. 1995 Transplant. Proc. pmid:8539799